25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GENO (Genovis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Genovis together

I guess you are interested in Genovis AB (publ.). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Genovis’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Genovis’s Price Targets

I'm going to help you getting a better view of Genovis AB (publ.). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Genovis AB (publ.)

I send you an email if I find something interesting about Genovis AB (publ.).

1. Quick Overview

1.1. Quick analysis of Genovis (30 sec.)










1.2. What can you expect buying and holding a share of Genovis? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr3.55
Expected worth in 1 year
kr3.97
How sure are you?
67.5%

+ What do you gain per year?

Total Gains per Share
kr0.42
Return On Investment
1.4%

For what price can you sell your share?

Current Price per Share
kr29.00
Expected price per share
kr26.10 - kr30.85
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genovis (5 min.)




Live pricePrice per Share (EOD)
kr29.00
Intrinsic Value Per Share
kr4.66 - kr15.16
Total Value Per Share
kr8.21 - kr18.71

2.2. Growth of Genovis (5 min.)




Is Genovis growing?

Current yearPrevious yearGrowGrow %
How rich?$24.4m$20.3m$3m13.1%

How much money is Genovis making?

Current yearPrevious yearGrowGrow %
Making money$621.4k$806.8k-$185.3k-29.8%
Net Profit Margin18.8%22.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Genovis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#489 / 872

Most Revenue
#378 / 872

Most Profit
#150 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genovis?

Welcome investor! Genovis's management wants to use your money to grow the business. In return you get a share of Genovis.

First you should know what it really means to hold a share of Genovis. And how you can make/lose money.

Speculation

The Price per Share of Genovis is kr29.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genovis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genovis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr3.55. Based on the TTM, the Book Value Change Per Share is kr0.10 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genovis.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%0.000.0%
Usd Book Value Change Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Price Per Share1.98-2.61-4.71-4.09-4.34-2.58-
Price to Earnings Ratio88.94-117.36--420.28--11.85-137.35-62.62-
Price-to-Total Gains Ratio266.52-355.99--10,501.47--3,082.59--1,273.01--609.40-
Price to Book Ratio5.29-7.34-15.23-14.86-21.15-19.94-
Price-to-Total Gains Ratio266.52-355.99--10,501.47--3,082.59--1,273.01--609.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.0508
Number of shares327
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.010.01
Gains per Quarter (327 shares)3.603.92
Gains per Year (327 shares)14.4115.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101440166
20291803122
30433204738
40584606354
50726007870
60867409486
70101880110102
801151020125118
901301160141134
1001441300157150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%22.018.00.055.0%22.044.00.033.3%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%27.013.00.067.5%33.030.03.050.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.066.00.0%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%27.013.00.067.5%33.030.03.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Genovis AB (publ.) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0700.105-33%0.134-48%0.134-48%0.114-38%0.085-17%
Book Value Per Share--3.5533.400+4%2.955+20%2.826+26%2.275+56%1.318+170%
Current Ratio--8.2678.552-3%8.249+0%8.100+2%7.200+15%5.083+63%
Debt To Asset Ratio--0.2950.305-3%0.281+5%0.245+20%0.215+37%0.273+8%
Debt To Equity Ratio--0.4190.438-5%0.414+1%0.343+22%0.288+45%0.442-5%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1132079108.9201640160557.205-31%2971552380.075-62%2588286998.835-56%2741311475.546-59%1622686159.743-30%
Eps--0.0530.090-42%0.117-55%0.123-57%0.109-51%0.042+25%
Ev To Sales Ratio--8.76413.494-35%23.956-63%21.760-60%27.089-68%53.337-84%
Free Cash Flow Per Share--0.1630.113+44%0.115+41%0.131+25%0.114+43%0.045+264%
Free Cash Flow To Equity Per Share--0.1630.106+53%0.092+76%0.115+42%0.097+67%0.078+109%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.050-5%
Intrinsic Value_10Y_max--15.162----------
Intrinsic Value_10Y_min--4.658----------
Intrinsic Value_1Y_max--0.668----------
Intrinsic Value_1Y_min--0.229----------
Intrinsic Value_3Y_max--2.656----------
Intrinsic Value_3Y_min--0.899----------
Intrinsic Value_5Y_max--5.426----------
Intrinsic Value_5Y_min--1.793----------
Market Cap1898505300.000+35%1229446108.9201622404057.205-24%2928772380.075-58%2547325486.502-52%2703013865.346-55%1603582617.768-23%
Net Profit Margin--0.1070.188-43%0.223-52%0.169-37%0.178-40%-2.040+2006%
Operating Margin---0.237-100%0.204-100%0.205-100%0.187-100%-1.9660%
Operating Ratio--0.9040.926-2%1.151-21%0.967-7%0.918-1%7.725-88%
Pb Ratio8.163+35%5.2867.341-28%15.233-65%14.862-64%21.146-75%19.938-73%
Pe Ratio137.334+35%88.936117.364-24%-420.277+573%-11.853+113%137.346-35%62.623+42%
Price Per Share29.000+35%18.78024.783-24%44.738-58%38.911-52%41.289-55%24.495-23%
Price To Free Cash Flow Ratio44.557+35%28.855-228.019+890%-66.037+329%647.792-96%268.831-89%122.817-77%
Price To Total Gains Ratio411.556+35%266.518355.989-25%-10501.469+4040%-3082.586+1257%-1273.013+578%-609.400+329%
Quick Ratio---5.215-100%6.424-100%5.746-100%5.062-100%3.333-100%
Return On Assets--0.0100.018-43%0.031-66%0.034-69%0.038-72%-0.021+301%
Return On Equity--0.0150.026-44%0.039-62%0.042-65%0.046-68%-0.046+410%
Total Gains Per Share--0.0700.105-33%0.134-48%0.134-48%0.114-38%0.085-17%
Usd Book Value--24467942.00023416967.700+4%20348231.100+20%19465624.052+26%15669588.560+56%9078423.139+170%
Usd Book Value Change Per Share--0.0070.011-33%0.014-48%0.014-48%0.012-38%0.009-17%
Usd Book Value Per Share--0.3740.358+4%0.311+20%0.297+26%0.239+56%0.139+170%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--119094722.258172544890.618-31%312607310.384-62%272287792.277-56%288385967.227-59%170706584.005-30%
Usd Eps--0.0060.009-42%0.012-55%0.013-57%0.011-51%0.004+25%
Usd Free Cash Flow--1120590.400780531.400+44%792708.300+41%900026.914+25%783365.919+43%308141.438+264%
Usd Free Cash Flow Per Share--0.0170.012+44%0.012+41%0.014+25%0.012+43%0.005+264%
Usd Free Cash Flow To Equity Per Share--0.0170.011+53%0.010+76%0.012+42%0.010+67%0.008+109%
Usd Market Cap199722757.560+35%129337730.658170676906.818-24%308106854.384-58%267978641.180-52%284357058.634-55%168696891.389-23%
Usd Price Per Share3.051+35%1.9762.607-24%4.706-58%4.093-52%4.344-55%2.577-23%
Usd Profit--363571.200621495.300-42%806805.100-55%848119.481-57%748808.098-51%290641.250+25%
Usd Revenue--3397118.4003224195.900+5%3393199.700+0%3439916.381-1%2989642.837+14%1911176.269+78%
Usd Total Gains Per Share--0.0070.011-33%0.014-48%0.014-48%0.012-38%0.009-17%
 EOD+4 -4MRQTTM+15 -21YOY+14 -223Y+14 -225Y+16 -2010Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of Genovis AB (publ.) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15137.334
Price to Book Ratio (EOD)Between0-18.163
Net Profit Margin (MRQ)Greater than00.107
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than18.267
Debt to Asset Ratio (MRQ)Less than10.295
Debt to Equity Ratio (MRQ)Less than10.419
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.010
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Genovis AB (publ.) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.722
Ma 20Greater thanMa 5027.305
Ma 50Greater thanMa 10025.865
Ma 100Greater thanMa 20024.268
OpenGreater thanClose28.850
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in KÀvlinge, Sweden.

Fundamental data was last updated by Penke on 2025-06-29 13:52:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Genovis earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compareΒ Genovis to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 10.7%Β means thatΒ kr0.11 for each kr1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genovis AB (publ.):

  • The MRQ is 10.7%. The company is making a huge profit. +2
  • The TTM is 18.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ10.7%TTM18.8%-8.1%
TTM18.8%YOY22.3%-3.5%
TTM18.8%5Y17.8%+1.0%
5Y17.8%10Y-204.0%+221.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.7%-92.7%+103.4%
TTM18.8%-140.3%+159.1%
YOY22.3%-196.4%+218.7%
3Y16.9%-248.5%+265.4%
5Y17.8%-343.4%+361.2%
10Y-204.0%-496.2%+292.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Genovis is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Genovis to theΒ Biotechnology industry mean.
  • 1.0% Return on Assets means thatΒ Genovis generatedΒ kr0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genovis AB (publ.):

  • The MRQ is 1.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.8%-0.8%
TTM1.8%YOY3.1%-1.2%
TTM1.8%5Y3.8%-1.9%
5Y3.8%10Y-2.1%+5.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-11.6%+12.6%
TTM1.8%-11.6%+13.4%
YOY3.1%-11.4%+14.5%
3Y3.4%-11.8%+15.2%
5Y3.8%-12.0%+15.8%
10Y-2.1%-13.7%+11.6%
4.3.1.3. Return on Equity

Shows how efficient Genovis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Genovis to theΒ Biotechnology industry mean.
  • 1.5% Return on Equity means Genovis generated kr0.01Β for eachΒ kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genovis AB (publ.):

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.5%TTM2.6%-1.2%
TTM2.6%YOY3.9%-1.3%
TTM2.6%5Y4.6%-2.0%
5Y4.6%10Y-4.6%+9.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%-13.6%+15.1%
TTM2.6%-15.0%+17.6%
YOY3.9%-14.5%+18.4%
3Y4.2%-16.9%+21.1%
5Y4.6%-17.5%+22.1%
10Y-4.6%-19.9%+15.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Genovis AB (publ.).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Genovis is operatingΒ .

  • Measures how much profit Genovis makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Genovis to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated kr0.00 Β for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genovis AB (publ.):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM23.7%-23.7%
TTM23.7%YOY20.4%+3.3%
TTM23.7%5Y18.7%+4.9%
5Y18.7%10Y-196.6%+215.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM23.7%-249.0%+272.7%
YOY20.4%-208.5%+228.9%
3Y20.5%-223.8%+244.3%
5Y18.7%-346.1%+364.8%
10Y-196.6%-475.5%+278.9%
4.3.2.2. Operating Ratio

Measures how efficient Genovis is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are kr0.90 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.904. The company is less efficient in keeping operating costs low.
  • The TTM is 0.926. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.904TTM0.926-0.021
TTM0.926YOY1.151-0.225
TTM0.9265Y0.918+0.008
5Y0.91810Y7.725-6.807
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9042.110-1.206
TTM0.9262.684-1.758
YOY1.1513.096-1.945
3Y0.9673.652-2.685
5Y0.9184.745-3.827
10Y7.7256.614+1.111
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Genovis AB (publ.).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genovis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 8.27Β means the company has kr8.27 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Genovis AB (publ.):

  • The MRQ is 8.267. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.552. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.267TTM8.552-0.285
TTM8.552YOY8.249+0.303
TTM8.5525Y7.200+1.352
5Y7.20010Y5.083+2.117
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.2673.661+4.606
TTM8.5523.846+4.706
YOY8.2494.140+4.109
3Y8.1004.688+3.412
5Y7.2005.746+1.454
10Y5.0836.147-1.064
4.4.3.2. Quick Ratio

Measures if Genovis is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Genovis to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off kr0.00 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.215-5.215
TTM5.215YOY6.424-1.209
TTM5.2155Y5.062+0.153
5Y5.06210Y3.333+1.729
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.826-2.826
TTM5.2153.182+2.033
YOY6.4243.786+2.638
3Y5.7464.311+1.435
5Y5.0625.703-0.641
10Y3.3336.454-3.121
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Genovis AB (publ.).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of GenovisΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Genovis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30Β means that Genovis assets areΒ financed with 29.5% credit (debt) and the remaining percentage (100% - 29.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.295. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.305. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.295TTM0.305-0.010
TTM0.305YOY0.281+0.023
TTM0.3055Y0.215+0.089
5Y0.21510Y0.273-0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2950.329-0.034
TTM0.3050.349-0.044
YOY0.2810.331-0.050
3Y0.2450.340-0.095
5Y0.2150.349-0.134
10Y0.2730.379-0.106
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Genovis is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Genovis to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 41.9% means that company has kr0.42 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.419. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.438. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.419TTM0.438-0.020
TTM0.438YOY0.414+0.025
TTM0.4385Y0.288+0.150
5Y0.28810Y0.442-0.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4190.379+0.040
TTM0.4380.437+0.001
YOY0.4140.4140.000
3Y0.3430.450-0.107
5Y0.2880.464-0.176
10Y0.4420.515-0.073
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every kr1 in earnings Genovis generates.

  • Above 15 is considered overpriced butΒ always compareΒ Genovis to theΒ Biotechnology industry mean.
  • A PE ratio of 88.94 means the investor is paying kr88.94Β for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genovis AB (publ.):

  • The EOD is 137.334. Based on the earnings, the company is expensive. -2
  • The MRQ is 88.936. Based on the earnings, the company is expensive. -2
  • The TTM is 117.364. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD137.334MRQ88.936+48.398
MRQ88.936TTM117.364-28.428
TTM117.364YOY-420.277+537.641
TTM117.3645Y137.346-19.983
5Y137.34610Y62.623+74.723
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD137.334-2.304+139.638
MRQ88.936-2.080+91.016
TTM117.364-2.564+119.928
YOY-420.277-3.764-416.513
3Y-11.853-3.773-8.080
5Y137.346-6.193+143.539
10Y62.623-6.833+69.456
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genovis AB (publ.):

  • The EOD is 44.557. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 28.855. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -228.019. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD44.557MRQ28.855+15.703
MRQ28.855TTM-228.019+256.874
TTM-228.019YOY-66.037-161.983
TTM-228.0195Y268.831-496.850
5Y268.83110Y122.817+146.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD44.557-3.132+47.689
MRQ28.855-2.705+31.560
TTM-228.019-3.666-224.353
YOY-66.037-4.405-61.632
3Y647.792-5.059+652.851
5Y268.831-8.477+277.308
10Y122.817-9.304+132.121
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Genovis is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 5.29 means the investor is paying kr5.29Β for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Genovis AB (publ.):

  • The EOD is 8.163. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.286. Based on the equity, the company is overpriced. -1
  • The TTM is 7.341. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.163MRQ5.286+2.877
MRQ5.286TTM7.341-2.055
TTM7.341YOY15.233-7.892
TTM7.3415Y21.146-13.805
5Y21.14610Y19.938+1.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.1631.953+6.210
MRQ5.2861.843+3.443
TTM7.3412.112+5.229
YOY15.2332.441+12.792
3Y14.8622.494+12.368
5Y21.1463.661+17.485
10Y19.9384.311+15.627
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Interest Income  13249181-1146753120-235-115



6.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets329,952
Total Liabilities97,367
Total Stockholder Equity232,585
 As reported
Total Liabilities 97,367
Total Stockholder Equity+ 232,585
Total Assets = 329,952

Assets

Total Assets329,952
Total Current Assets214,733
Long-term Assets115,219
Total Current Assets
Cash And Cash Equivalents 175,410
Other Current Assets 39,323
Total Current Assets  (as reported)214,733
Total Current Assets  (calculated)214,733
+/-0
Long-term Assets
Property Plant Equipment 87,417
Long-term Assets  (as reported)115,219
Long-term Assets  (calculated)87,417
+/- 27,802

Liabilities & Shareholders' Equity

Total Current Liabilities25,976
Long-term Liabilities71,391
Total Stockholder Equity232,585
Total Current Liabilities
Total Current Liabilities  (as reported)25,976
Total Current Liabilities  (calculated)0
+/- 25,976
Long-term Liabilities
Long-term Liabilities Other 71,391
Long-term Liabilities  (as reported)71,391
Long-term Liabilities  (calculated)71,391
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)232,585
Total Stockholder Equity (calculated)0
+/- 232,585
Other
Common Stock Shares Outstanding 65,466
Net Working Capital 188,757



6.3. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-03-31
> Total Assets 
0
16,564
0
0
14,759
14,544
25,724
20,737
17,818
14,500
28,370
24,895
21,442
18,165
29,650
25,801
18,158
13,311
23,852
20,103
41,448
37,888
33,601
27,790
19,562
16,509
25,180
17,822
16,914
21,660
26,314
23,157
21,851
19,196
26,347
24,972
26,305
30,573
42,719
39,203
37,827
39,585
42,792
54,611
49,044
95,332
98,841
98,123
106,648
107,932
106,667
106,365
141,750
147,062
149,323
157,317
150,520
196,368
211,084
292,719
288,857
303,300
303,429
319,345
327,412
329,952
329,952327,412319,345303,429303,300288,857292,719211,084196,368150,520157,317149,323147,062141,750106,365106,667107,932106,64898,12398,84195,33249,04454,61142,79239,58537,82739,20342,71930,57326,30524,97226,34719,19621,85123,15726,31421,66016,91417,82225,18016,50919,56227,79033,60137,88841,44820,10323,85213,31118,15825,80129,65018,16521,44224,89528,37014,50017,81820,73725,72414,54414,7590016,5640
   > Total Current Assets 
0
2,925
0
0
1,911
2,012
13,493
8,746
5,499
2,211
16,249
12,912
9,715
6,286
17,673
13,968
10,067
4,834
15,006
11,380
32,040
27,488
22,883
17,093
10,103
6,772
15,190
11,563
10,818
15,657
20,004
16,836
15,612
12,396
19,394
18,144
17,523
14,773
25,603
25,343
27,148
28,934
31,195
41,586
34,637
80,990
68,541
69,295
72,076
73,189
73,047
72,868
108,852
108,231
109,701
113,406
106,970
152,998
155,920
160,727
159,040
177,953
180,006
199,340
208,187
214,733
214,733208,187199,340180,006177,953159,040160,727155,920152,998106,970113,406109,701108,231108,85272,86873,04773,18972,07669,29568,54180,99034,63741,58631,19528,93427,14825,34325,60314,77317,52318,14419,39412,39615,61216,83620,00415,65710,81811,56315,1906,77210,10317,09322,88327,48832,04011,38015,0064,83410,06713,96817,6736,2869,71512,91216,2492,2115,4998,74613,4932,0121,911002,9250
       Cash And Cash Equivalents 
0
1,911
0
0
416
1,037
11,863
7,125
4,074
1,008
14,161
11,035
7,563
3,959
14,772
10,918
6,684
1,543
10,851
4,470
480
5,080
4,329
7,003
689
1,724
9,240
6,145
2,052
3,332
10,011
6,599
4,281
1,805
8,194
6,490
4,918
1,672
10,293
10,236
9,581
11,025
8,921
15,303
14,992
61,641
46,554
46,231
44,118
45,929
41,730
45,210
81,315
78,119
77,369
80,987
72,830
115,397
114,198
119,131
123,261
136,793
135,809
155,534
169,442
175,410
175,410169,442155,534135,809136,793123,261119,131114,198115,39772,83080,98777,36978,11981,31545,21041,73045,92944,11846,23146,55461,64114,99215,3038,92111,0259,58110,23610,2931,6724,9186,4908,1941,8054,2816,59910,0113,3322,0526,1459,2401,7246897,0034,3295,0804804,47010,8511,5436,68410,91814,7723,9597,56311,03514,1611,0084,0747,12511,8631,037416001,9110
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,232
3,000
3,000
18,000
12,500
5,000
5,000
0
3,436
3,436
0
3,436
3,436
3,436
0
3,436
3,436
3,436
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000003,4363,4363,43603,4363,4363,43603,4363,43605,0005,00012,50018,0003,0003,0007,232000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,276
0
0
0
0
0
0
0
1,879
0
0
0
2,271
0
0
0
4,569
0
0
0
4,090
0
0
0
5,933
0
0
0
7,059
0
0
0
11,213
0
0
0
15,118
0
0
0
16,913
0
0
0
17,655
0
0
0
17,428
0
017,42800017,65500016,91300015,11800011,2130007,0590005,9330004,0900004,5690002,2710001,87900000001,2760000000000000000
       Other Current Assets 
0
507
0
0
775
292
857
970
880
763
724
1,246
1,755
2,018
2,901
3,050
2,978
3,291
4,155
3,910
28,075
4,408
6,054
5,090
1,670
5,048
5,950
5,418
5,535
12,325
9,993
10,237
8,940
10,591
11,200
11,654
9,058
13,101
15,310
15,107
5,894
17,909
22,274
26,283
3,620
19,349
21,987
23,064
3,860
27,260
31,317
27,658
0
30,112
32,332
32,419
4,669
37,601
41,722
41,596
6,118
41,160
44,197
43,806
38,745
39,323
39,32338,74543,80644,19741,1606,11841,59641,72237,6014,66932,41932,33230,112027,65831,31727,2603,86023,06421,98719,3493,62026,28322,27417,9095,89415,10715,31013,1019,05811,65411,20010,5918,94010,2379,99312,3255,5355,4185,9505,0481,6705,0906,0544,40828,0753,9104,1553,2912,9783,0502,9012,0181,7551,246724763880970857292775005070
   > Long-term Assets 
0
13,639
0
0
12,849
12,532
12,231
11,991
12,319
12,289
12,121
11,983
11,726
11,879
11,977
11,833
8,091
8,477
8,846
8,723
9,408
10,400
10,718
10,697
9,459
9,737
9,990
6,259
6,096
6,003
6,310
6,321
6,239
6,800
6,953
6,828
8,782
15,800
17,116
13,860
10,679
10,651
11,597
13,025
14,406
14,342
30,300
28,828
34,572
34,743
33,620
33,497
32,898
38,831
39,622
43,911
43,551
43,370
55,164
131,992
129,817
125,347
123,423
120,005
119,225
115,219
115,219119,225120,005123,423125,347129,817131,99255,16443,37043,55143,91139,62238,83132,89833,49733,62034,74334,57228,82830,30014,34214,40613,02511,59710,65110,67913,86017,11615,8008,7826,8286,9536,8006,2396,3216,3106,0036,0966,2599,9909,7379,45910,69710,71810,4009,4088,7238,8468,4778,09111,83311,97711,87911,72611,98312,12112,28912,31911,99112,23112,53212,8490013,6390
       Property Plant Equipment 
0
1,516
0
0
1,948
1,776
1,619
1,523
1,520
1,434
1,357
1,344
1,390
1,341
1,417
1,372
1,290
1,560
1,614
1,517
1,810
2,477
2,312
2,152
2,307
2,130
2,036
1,854
1,756
1,589
1,414
1,245
1,084
1,356
1,189
1,029
3,022
10,585
12,215
9,264
6,350
6,279
7,268
8,777
9,470
9,176
10,181
9,613
12,497
12,208
11,340
10,713
9,604
13,055
12,267
14,823
15,812
15,982
18,329
96,360
95,255
93,578
91,360
89,518
89,164
87,417
87,41789,16489,51891,36093,57895,25596,36018,32915,98215,81214,82312,26713,0559,60410,71311,34012,20812,4979,61310,1819,1769,4708,7777,2686,2796,3509,26412,21510,5853,0221,0291,1891,3561,0841,2451,4141,5891,7561,8542,0362,1302,3072,1522,3122,4771,8101,5171,6141,5601,2901,3721,4171,3411,3901,3441,3571,4341,5201,5231,6191,7761,948001,5160
       Goodwill 
0
0
0
0
0
0
0
0
0
0
4,107
4,106
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,729
0
0
0
4,118
0
0
0
4,753
0
0
0
4,573
0
0
0
0
0
000004,5730004,7530004,1180003,7290000000000000000000000000000000000004,1064,1070000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,718
1,718
0
1,718
0
1,718
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,71801,71801,7181,7180000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
3,766
3,632
0
7,373
0
7,220
3,426
3,532
3,796
3,770
4,162
4,487
4,970
5,109
5,434
5,889
6,236
2,687
2,622
2,696
3,178
3,358
3,438
3,726
4,046
4,081
4,042
3,497
3,183
2,878
2,611
2,654
2,611
2,530
3,218
3,448
18,321
17,420
12,103
16,315
16,236
16,384
12,357
16,639
17,774
18,663
12,723
17,227
17,989
18,077
12,821
18,338
19,431
0
8,262
0
08,262019,43118,33812,82118,07717,98917,22712,72318,66317,77416,63912,35716,38416,23616,31512,10317,42018,3213,4483,2182,5302,6112,6542,6112,8783,1833,4974,0424,0814,0463,7263,4383,3583,1782,6962,6222,6876,2365,8895,4345,1094,9704,4874,1623,7703,7963,5323,4267,22007,37303,6323,7660000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
3,626
1,795
6,243
6,220
6,044
6,400
6,818
9,137
9,581
10,425
10,263
10,073
18,754
0
0
0
0
0
0
0
000000018,75410,07310,26310,4259,5819,1376,8186,4006,0446,2206,2431,7953,6261,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,71800000000000000000000000000000000
> Total Liabilities 
0
4,435
0
0
3,902
6,093
4,327
2,204
2,586
2,876
2,972
2,505
3,431
4,340
4,465
3,837
4,525
3,741
4,810
3,801
8,363
5,234
5,611
5,346
4,979
6,932
6,720
5,897
8,092
16,292
7,257
5,228
6,306
6,523
5,262
5,528
8,119
13,781
18,225
14,417
11,756
11,923
13,750
18,096
13,423
11,947
18,690
17,308
19,482
19,161
16,862
15,547
27,756
19,985
21,433
24,517
24,868
26,373
24,246
101,830
98,047
98,140
95,803
97,149
99,440
97,367
97,36799,44097,14995,80398,14098,047101,83024,24626,37324,86824,51721,43319,98527,75615,54716,86219,16119,48217,30818,69011,94713,42318,09613,75011,92311,75614,41718,22513,7818,1195,5285,2626,5236,3065,2287,25716,2928,0925,8976,7206,9324,9795,3465,6115,2348,3633,8014,8103,7414,5253,8374,4654,3403,4312,5052,9722,8762,5862,2044,3276,0933,902004,4350
   > Total Current Liabilities 
0
2,890
0
0
2,967
5,159
3,811
1,873
2,281
2,571
2,667
2,260
3,367
4,335
4,460
3,832
4,525
3,741
4,810
3,801
8,363
5,234
5,611
5,346
4,799
6,752
6,540
5,717
7,958
16,157
7,122
5,093
6,306
6,523
5,262
5,528
6,363
6,404
8,531
6,960
8,815
8,983
10,810
13,415
11,289
9,965
12,333
11,735
13,744
14,103
13,196
12,251
24,245
12,099
13,200
14,239
18,005
19,683
17,350
19,977
21,225
21,005
18,779
22,217
28,195
25,976
25,97628,19522,21718,77921,00521,22519,97717,35019,68318,00514,23913,20012,09924,24512,25113,19614,10313,74411,73512,3339,96511,28913,41510,8108,9838,8156,9608,5316,4046,3635,5285,2626,5236,3065,0937,12216,1577,9585,7176,5406,7524,7995,3465,6115,2348,3633,8014,8103,7414,5253,8324,4604,3353,3672,2602,6672,5712,2811,8733,8115,1592,967002,8900
       Short-term Debt 
0
0
0
0
480
0
0
0
120
0
0
0
180
0
0
0
0
0
0
0
0
0
0
0
46
0
0
0
46
0
0
0
135
0
0
0
143
7,377
9,694
626
2,231
0
0
0
5,094
0
0
0
3,344
0
3,238
2,984
1,708
966
317
2,574
2,885
2,036
1,163
992
4,513
3,464
2,447
0
0
0
0002,4473,4644,5139921,1632,0362,8852,5743179661,7082,9843,23803,3440005,0940002,2316269,6947,3771430001350004600046000000000001800001200004800000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135
0
0
0
352
7,377
9,694
626
2,231
0
0
0
2,547
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,5470002,2316269,6947,37735200013500000000000000000000000000000000
       Accounts payable 
0
0
0
0
747
0
0
0
563
0
0
0
648
0
0
3,832
1,224
0
0
0
3,557
0
0
0
986
0
0
0
945
0
0
0
1,552
0
0
0
1,332
0
0
0
1,308
0
0
0
1,662
0
0
0
1,466
0
9,958
9,267
2,537
0
12,883
11,665
5,452
0
16,187
18,985
4,302
0
16,332
0
3,374
0
03,374016,33204,30218,98516,18705,45211,66512,88302,5379,2679,95801,4660001,6620001,3080001,3320001,5520009450009860003,5570001,2243,832006480005630007470000
       Other Current Liabilities 
0
2,890
0
0
316
5,159
3,811
1,873
12
2,571
2,667
2,260
131
4,335
4,460
3,832
3,301
3,741
4,810
3,801
4,807
5,234
5,611
5,346
3,767
6,752
6,540
5,717
6,967
16,157
7,122
5,093
4,620
6,523
5,262
5,528
4,342
6,404
8,531
6,960
5,277
8,983
10,810
13,415
4,533
9,965
12,333
11,735
8,934
14,103
3,238
2,984
1,281
12,099
317
2,574
9,668
19,683
1,163
992
12,410
21,005
2,447
22,217
28,195
0
028,19522,2172,44721,00512,4109921,16319,6839,6682,57431712,0991,2812,9843,23814,1038,93411,73512,3339,9654,53313,41510,8108,9835,2776,9608,5316,4044,3425,5285,2626,5234,6205,0937,12216,1576,9675,7176,5406,7523,7675,3465,6115,2344,8073,8014,8103,7413,3013,8324,4604,3351312,2602,6672,571121,8733,8115,159316002,8900
   > Long-term Liabilities 
0
1,545
0
0
935
934
516
331
305
305
305
245
65
5
5
5
0
0
0
0
0
0
0
0
180
180
180
180
135
135
135
135
0
0
0
0
1,755
7,377
9,694
7,457
2,940
2,940
2,940
4,681
2,134
1,982
6,357
5,573
5,739
5,058
3,666
3,296
3,511
7,886
8,233
10,278
6,863
6,690
6,896
81,853
76,822
77,135
77,024
74,932
71,245
71,391
71,39171,24574,93277,02477,13576,82281,8536,8966,6906,86310,2788,2337,8863,5113,2963,6665,0585,7395,5736,3571,9822,1344,6812,9402,9402,9407,4579,6947,3771,75500001351351351351801801801800000000055565245305305305331516934935001,5450
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,123
0
0
0
4,438
0
0
0
0
0
0
0
0
0
0000000004,4380001,1230000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,377
9,694
0
2,940
0
0
0
0
1,982
4,789
2,729
2,421
2,923
2,381
2,391
2,387
7,886
2,536
10,278
2,425
2,324
2,349
0
0
0
0
0
0
0
00000002,3492,3242,42510,2782,5367,8862,3872,3912,3812,9232,4212,7294,7891,98200002,94009,6947,3770000000000000000000000000000000000000
> Total Stockholder Equity
0
12,129
0
0
10,858
8,451
21,397
18,533
15,232
11,624
25,398
22,390
18,010
13,825
25,185
21,964
13,633
9,570
19,042
16,302
33,085
32,654
27,990
22,444
14,583
9,577
18,460
11,925
8,822
5,368
19,057
17,929
15,545
12,673
21,085
19,444
18,187
16,792
24,494
24,786
26,071
27,662
29,042
36,515
35,621
83,385
80,151
80,815
87,165
88,771
89,805
90,818
113,994
127,077
127,890
132,800
125,652
169,995
186,838
190,889
190,810
205,160
207,626
222,196
227,972
232,585
232,585227,972222,196207,626205,160190,810190,889186,838169,995125,652132,800127,890127,077113,99490,81889,80588,77187,16580,81580,15183,38535,62136,51529,04227,66226,07124,78624,49416,79218,18719,44421,08512,67315,54517,92919,0575,3688,82211,92518,4609,57714,58322,44427,99032,65433,08516,30219,0429,57013,63321,96425,18513,82518,01022,39025,39811,62415,23218,53321,3978,45110,8580012,1290
   Common Stock
0
0
0
0
9,836
0
0
0
16,449
0
0
0
27,695
0
0
21,964
4,734
9,570
19,042
16,302
6,312
32,654
27,990
22,444
8,738
9,577
18,460
11,925
9,216
5,368
19,057
17,929
13,824
12,673
21,085
19,444
15,074
16,792
24,494
24,786
15,775
27,662
29,042
36,515
15,775
83,385
80,151
80,815
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
16,366
207,626
0
0
0
000207,62616,36616,36616,36616,36616,36616,36616,36616,36616,36616,36616,36616,36616,36616,36680,81580,15183,38515,77536,51529,04227,66215,77524,78624,49416,79215,07419,44421,08512,67313,82417,92919,0575,3689,21611,92518,4609,5778,73822,44427,99032,6546,31216,30219,0429,5704,73421,9640027,69500016,4490009,8360000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,104
0
0
0
0
0
0
0
0
0
0
0
-10
0
0
0
-175
0
0
0
-24
0
0
0
-27
0
0
0
-4,500
16,366
0
0
-2,449
0
0
116,434
-1,021
0
0
174,523
174,444
0
0
0
0
0
00000174,444174,52300-1,021116,43400-2,4490016,366-4,500000-27000-24000-175000-10000000000002,10400000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
12,129
0
0
69,982
8,451
21,397
18,533
10,075
11,624
25,398
22,390
84,477
13,825
25,185
21,964
98,050
9,570
19,042
16,302
131,777
32,654
27,990
22,444
132,898
9,577
18,460
11,925
126,720
5,368
19,057
17,929
120,860
12,673
21,085
19,444
157,931
16,792
24,494
24,786
166,674
27,662
29,042
36,515
166,674
83,385
80,151
80,815
215,655
56,038
73,439
74,452
213,206
110,711
111,524
132,800
214,633
153,629
170,472
174,523
215,655
188,794
191,260
222,196
227,972
0
0227,972222,196191,260188,794215,655174,523170,472153,629214,633132,800111,524110,711213,20674,45273,43956,038215,65580,81580,15183,385166,67436,51529,04227,662166,67424,78624,49416,792157,93119,44421,08512,673120,86017,92919,0575,368126,72011,92518,4609,577132,89822,44427,99032,654131,77716,30219,0429,57098,05021,96425,18513,82584,47722,39025,39811,62410,07518,53321,3978,45169,9820012,1290



6.4. Balance Sheets

Currency in SEK. All numbers in thousands.




6.5. Cash Flows

Currency in SEK. All numbers in thousands.




6.6. Income Statements

Currency in SEK. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue130,358
Cost of Revenue-15,387
Gross Profit114,971114,971
 
Operating Income (+$)
Gross Profit114,971
Operating Expense-69,239
Operating Income45,73245,732
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense69,2390
 
Net Interest Income (+$)
Interest Income4,456
Interest Expense-3,956
Other Finance Cost-0
Net Interest Income500
 
Pretax Income (+$)
Operating Income45,732
Net Interest Income500
Other Non-Operating Income Expenses0
Income Before Tax (EBT)46,32945,135
EBIT - interestExpense = 41,776
46,329
36,872
Interest Expense3,956
Earnings Before Interest and Taxes (EBIT)45,73250,285
Earnings Before Interest and Taxes (EBITDA)56,178
 
After tax Income (+$)
Income Before Tax46,329
Tax Provision-13,413
Net Income From Continuing Ops32,91632,916
Net Income32,916
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses84,626
Total Other Income/Expenses Net597-500
 

Technical Analysis of Genovis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genovis. The general trend of Genovis is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genovis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Genovis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genovis AB (publ.).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 29.90 < 30.45 < 30.85.

The bearish price targets are: 27.50 > 27.50 > 26.10.

Know someone who trades $GENO? Share this with them.πŸ‘‡

Genovis AB (publ.) Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genovis AB (publ.). The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genovis AB (publ.) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genovis AB (publ.). The current macd is 0.9224568.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genovis price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Genovis. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Genovis price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Genovis AB (publ.) Daily Moving Average Convergence/Divergence (MACD) ChartGenovis AB (publ.) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genovis AB (publ.). The current adx is 15.94.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Genovis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Genovis AB (publ.) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genovis AB (publ.). The current sar is 27.19.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Genovis AB (publ.) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genovis AB (publ.). The current rsi is 64.72. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Genovis AB (publ.) Daily Relative Strength Index (RSI) ChartGenovis AB (publ.) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genovis AB (publ.). The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genovis price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Genovis AB (publ.) Daily Stochastic Oscillator ChartGenovis AB (publ.) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genovis AB (publ.). The current cci is 134.25.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Genovis AB (publ.) Daily Commodity Channel Index (CCI) ChartGenovis AB (publ.) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genovis AB (publ.). The current cmo is 32.43.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Genovis AB (publ.) Daily Chande Momentum Oscillator (CMO) ChartGenovis AB (publ.) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genovis AB (publ.). The current willr is -20.25316456.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genovis is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Genovis AB (publ.) Daily Williams %R ChartGenovis AB (publ.) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Genovis AB (publ.).

Genovis AB (publ.) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genovis AB (publ.). The current atr is 1.22044797.

Genovis AB (publ.) Daily Average True Range (ATR) ChartGenovis AB (publ.) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genovis AB (publ.). The current obv is -1,702,072.

Genovis AB (publ.) Daily On-Balance Volume (OBV) ChartGenovis AB (publ.) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genovis AB (publ.). The current mfi is 59.42.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Genovis AB (publ.) Daily Money Flow Index (MFI) ChartGenovis AB (publ.) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genovis AB (publ.).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Genovis AB (publ.) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genovis AB (publ.) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.722
Ma 20Greater thanMa 5027.305
Ma 50Greater thanMa 10025.865
Ma 100Greater thanMa 20024.268
OpenGreater thanClose28.850
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Genovis with someone you think should read this too:
  • Are you bullish or bearish on Genovis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genovis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genovis AB (publ.)

I send you an email if I find something interesting about Genovis AB (publ.).


Comments

How you think about this?

Leave a comment

Stay informed about Genovis AB (publ.).

Receive notifications about Genovis AB (publ.) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.